Cream for external use 0.2%.
Tube 50 g.
CodeATX [D 11 AX 12]
Pharmacological properties of
Activated zinc pyrithione has anti-inflammatory, antibacterial and antifungal activity. Antifungal activity is especially pronounced against Pityrosporum ovale and Pityrosporum orbiculare, which support inflammation and excessive desquamation during dandruff, seborrhea, psoriasis and other skin diseases. Zinc pyrithione reduces intracellular ATP levels, contributes to the depolarization of cell membranes and the death of fungi and bacteria.
For external use, activated pyrithione zinc is deposited in the epidermis and surface layers of the dermis. Systemic absorption occurs slowly. The drug is found in the blood in trace amounts.
Psoriasis, atopic dermatitis, eczema, neurodermatitis, dry skin, seborrheic dermatitis in adults and children from 1 year old.
Hypersensitivity to the components of the drug.
Use during pregnancy and lactation
During pregnancy and lactation, the drug should be prescribed only in cases where the expected benefits of therapy for the mother outweigh the potential risk to the fetus or infant.
No adverse effects were reported with the use of zinc pyrithione preparations by pregnant women and women during breastfeeding.
In case of contact with eyes, rinse with plenty of cold water.
100 g of the preparation contain:
pyrithione zinc activated 200 mg
glyceryl mono- and distearate (Tegin M),
capryl caprylate (Tegosstroper ether, Tegospert Erod,) Tegosoft E20),
isopropyl palmitate (Tegosoft R),
methyl dextrose polyglyceryl distearate (Togo Car 450),
propyl parahydroxybenzoic acid (s) fatty acid and hydrochloride acid alcohol (tego alkano l 18),
flavoring agent (citronellol, phenylethanol, geraniol, terpineol, cinnamon alcohol),
cyclomethicone (Abil K 4),
Dosage and Administration
Externally. After vigorous shaking, the cream is applied in a thin layer to the affected areas of the skin 2 times a day. The course of treatment for psoriasis is 1-1.5 months, with atopic dermatitis 3-4 weeks.
Method of administration and doses in pediatrics: method of administration and doses in children do not differ from the method of administration and doses in adults.
If necessary, a second course of treatment can be carried out 1-1.5 months after consulting a doctor.
In the first days of treatment, there may be a short-term burning sensation at the site of application of the drug, which, as a rule, does not require discontinuation of the drug.
No clinically significant interactions of Skin-cap with other drugs have been identified.
At a temperature of +4 to +20 ° C, out of the reach of children.
l.Bra.A.Bra. Raun Medical SA, Spain